A citation-based method for searching scientific literature

Ganesh Umapathy, Patricia Mendoza-Garcia, Bengt Hallberg, Ruth H Palmer. APMIS 2019
Times Cited: 31







List of co-cited articles
306 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The genetic landscape of high-risk neuroblastoma.
Trevor J Pugh, Olena Morozova, Edward F Attiyeh, Shahab Asgharzadeh, Jun S Wei, Daniel Auclair, Scott L Carter, Kristian Cibulskis, Megan Hanna, Adam Kiezun,[...]. Nat Genet 2013
701
48

Identification of ALK as a major familial neuroblastoma predisposition gene.
Yaël P Mossé, Marci Laudenslager, Luca Longo, Kristina A Cole, Andrew Wood, Edward F Attiyeh, Michael J Laquaglia, Rachel Sennett, Jill E Lynch, Patrizia Perri,[...]. Nature 2008
881
48

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Isabelle Janoueix-Lerosey, Delphine Lequin, Laurence Brugières, Agnès Ribeiro, Loïc de Pontual, Valérie Combaret, Virginie Raynal, Alain Puisieux, Gudrun Schleiermacher, Gaëlle Pierron,[...]. Nature 2008
616
45

Oncogenic mutations of ALK kinase in neuroblastoma.
Yuyan Chen, Junko Takita, Young Lim Choi, Motohiro Kato, Miki Ohira, Masashi Sanada, Lili Wang, Manabu Soda, Akira Kikuchi, Takashi Igarashi,[...]. Nature 2008
640
35


The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Teeara Berry, William Luther, Namrata Bhatnagar, Yann Jamin, Evon Poon, Takaomi Sanda, Desheng Pei, Bandana Sharma, Winston R Vetharoy, Albert Hallsworth,[...]. Cancer Cell 2012
209
32

Recent advances in neuroblastoma.
John M Maris. N Engl J Med 2010
32

Activating mutations in ALK provide a therapeutic target in neuroblastoma.
Rani E George, Takaomi Sanda, Megan Hanna, Stefan Fröhling, William Luther, Jianming Zhang, Yebin Ahn, Wenjun Zhou, Wendy B London, Patrick McGrady,[...]. Nature 2008
622
32

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Thomas F Eleveld, Derek A Oldridge, Virginie Bernard, Jan Koster, Léo Colmet Daage, Sharon J Diskin, Linda Schild, Nadia Bessoltane Bentahar, Angela Bellini, Mathieu Chicard,[...]. Nat Genet 2015
311
29

The role of the ALK receptor in cancer biology.
B Hallberg, R H Palmer. Ann Oncol 2016
159
29

Emergence of new ALK mutations at relapse of neuroblastoma.
Gudrun Schleiermacher, Niloufar Javanmardi, Virginie Bernard, Quentin Leroy, Julie Cappo, Thomas Rio Frio, Gaelle Pierron, Eve Lapouble, Valérie Combaret, Frank Speleman,[...]. J Clin Oncol 2014
115
29

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.
Andrey V Reshetnyak, Phillip B Murray, Xiarong Shi, Elizabeth S Mo, Jyotidarsini Mohanty, Francisco Tome, Hanwen Bai, Murat Gunel, Irit Lax, Joseph Schlessinger. Proc Natl Acad Sci U S A 2015
88
29

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.
Jikui Guan, Ganesh Umapathy, Yasuo Yamazaki, Georg Wolfstetter, Patricia Mendoza, Kathrin Pfeifer, Ateequrrahman Mohammed, Fredrik Hugosson, Hongbing Zhang, Amy W Hsu,[...]. Elife 2015
89
25

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Yael P Mossé, Megan S Lim, Stephan D Voss, Keith Wilner, Katherine Ruffner, Julie Laliberte, Delphine Rolland, Frank M Balis, John M Maris, Brenda J Weigel,[...]. Lancet Oncol 2013
451
25

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Alex Cazes, Lucille Lopez-Delisle, Konstantina Tsarovina, Cécile Pierre-Eugène, Katleen De Preter, Michel Peuchmaur, André Nicolas, Claire Provost, Caroline Louis-Brennetot, Romain Daveau,[...]. Oncotarget 2014
61
25


Neuroblastoma.
John M Maris, Michael D Hogarty, Rochelle Bagatell, Susan L Cohn. Lancet 2007
25

Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
Shizhen Zhu, Jeong-Soo Lee, Feng Guo, Jimann Shin, Antonio R Perez-Atayde, Jeffery L Kutok, Scott J Rodig, Donna S Neuberg, Daniel Helman, Hui Feng,[...]. Cancer Cell 2012
218
25

ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells.
Andrey Fadeev, Patricia Mendoza-Garcia, Uwe Irion, Jikui Guan, Kathrin Pfeifer, Stephanie Wiessner, Fabrizio Serluca, Ajeet Pratap Singh, Christiane Nüsslein-Volhard, Ruth H Palmer. Proc Natl Acad Sci U S A 2018
44
25

ALK in Neuroblastoma: Biological and Therapeutic Implications.
Ricky M Trigg, Suzanne D Turner. Cancers (Basel) 2018
65
25

Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.
Kristina B Emdal, Anna-Kathrine Pedersen, Dorte B Bekker-Jensen, Alicia Lundby, Shana Claeys, Katleen De Preter, Frank Speleman, Chiara Francavilla, Jesper V Olsen. Sci Signal 2018
20
35

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Jimmy Van den Eynden, Ganesh Umapathy, Arghavan Ashouri, Diana Cervantes-Madrid, Joanna Szydzik, Kristina Ruuth, Jan Koster, Erik Larsson, Jikui Guan, Ruth H Palmer,[...]. Sci Signal 2018
17
41

Neuroblastoma.
Katherine K Matthay, John M Maris, Gudrun Schleiermacher, Akira Nakagawara, Crystal L Mackall, Lisa Diller, William A Weiss. Nat Rev Dis Primers 2016
552
22

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
Sara De Brouwer, Katleen De Preter, Candy Kumps, Piotr Zabrocki, Michaël Porcu, Ellen M Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmien Hoebeeck, Tom Van Maerken,[...]. Clin Cancer Res 2010
187
22

Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk.
Elizabeth S Mo, Qianni Cheng, Andrey V Reshetnyak, Joseph Schlessinger, Stefania Nicoli. Proc Natl Acad Sci U S A 2017
41
22

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
Susan L Cohn, Andrew D J Pearson, Wendy B London, Tom Monclair, Peter F Ambros, Garrett M Brodeur, Andreas Faldum, Barbara Hero, Tomoko Iehara, David Machin,[...]. J Clin Oncol 2009
22

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Scott C Bresler, Daniel A Weiser, Peter J Huwe, Jin H Park, Kateryna Krytska, Hannah Ryles, Marci Laudenslager, Eric F Rappaport, Andrew C Wood, Patrick W McGrady,[...]. Cancer Cell 2014
222
19

Targeted expression of MYCN causes neuroblastoma in transgenic mice.
W A Weiss, K Aldape, G Mohapatra, B G Feuerstein, J M Bishop. EMBO J 1997
604
19

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
S W Morris, M N Kirstein, M B Valentine, K G Dittmer, D N Shapiro, D L Saltman, A T Look. Science 1994
19

Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
Lucille Lopez-Delisle, Cécile Pierre-Eugène, Caroline Louis-Brennetot, Didier Surdez, Virginie Raynal, Sylvain Baulande, Valentina Boeva, Sandrine Grossetête-Lalami, Valérie Combaret, Michel Peuchmaur,[...]. Oncogene 2018
28
21

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
19

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.
Muhammad Wasi Alam, Marcus Borenäs, Dan E Lind, Diana Cervantes-Madrid, Ganesh Umapathy, Ruth H Palmer, Bengt Hallberg. Front Oncol 2019
15
40

ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Marcus Borenäs, Ganesh Umapathy, Wei-Yun Lai, Dan E Lind, Barbara Witek, Jikui Guan, Patricia Mendoza-Garcia, Tafheem Masudi, Arne Claeys, Tzu-Po Chuang,[...]. EMBO J 2021
17
35

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
J Guan, E R Tucker, H Wan, D Chand, L S Danielson, K Ruuth, A El Wakil, B Witek, Y Jamin, G Umapathy,[...]. Dis Model Mech 2016
52
16

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.
Tommy Martinsson, Therese Eriksson, Jonas Abrahamsson, Helena Caren, Magnus Hansson, Per Kogner, Sattu Kamaraj, Christina Schönherr, Joel Weinmar, Kristina Ruuth,[...]. Cancer Res 2011
54
16

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Jikui Guan, Susanne Fransson, Joachim Tetteh Siaw, Diana Treis, Jimmy Van den Eynden, Damini Chand, Ganesh Umapathy, Kristina Ruuth, Petter Svenberg, Sandra Wessman,[...]. Cold Spring Harb Mol Case Stud 2018
29
17

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Ganesh Umapathy, Jikui Guan, Dan E Gustafsson, Niloufar Javanmardi, Diana Cervantes-Madrid, Anna Djos, Tommy Martinsson, Ruth H Palmer, Bengt Hallberg. Sci Signal 2017
32
16

Targeting ALK: Precision Medicine Takes on Drug Resistance.
Jessica J Lin, Gregory J Riely, Alice T Shaw. Cancer Discov 2017
279
16

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Nicole R Infarinato, Jin H Park, Kateryna Krytska, Hannah T Ryles, Renata Sano, Katherine M Szigety, Yimei Li, Helen Y Zou, Nathan V Lee, Tod Smeal,[...]. Cancer Discov 2016
100
16

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
Lukas C Heukamp, Theresa Thor, Alexander Schramm, Katleen De Preter, Candy Kumps, Bram De Wilde, Andrea Odersky, Martin Peifer, Sven Lindner, Annika Spruessel,[...]. Sci Transl Med 2012
116
16

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
T Iwahara, J Fujimoto, D Wen, R Cupples, N Bucay, T Arakawa, S Mori, B Ratzkin, T Yamamoto. Oncogene 1997
503
16

Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin.
Christel Moog-Lutz, Joffrey Degoutin, Jean Y Gouzi, Yvelyne Frobert, Nicole Brunet-de Carvalho, Jocelyne Bureau, Christophe Créminon, Marc Vigny. J Biol Chem 2005
115
16

Characterization of the expression of the ALK receptor tyrosine kinase in mice.
Emma Vernersson, Nelson K S Khoo, Maria L Henriksson, Göran Roos, Ruth H Palmer, Bengt Hallberg. Gene Expr Patterns 2006
104
16

Neuroblastoma is composed of two super-enhancer-associated differentiation states.
Tim van Groningen, Jan Koster, Linda J Valentijn, Danny A Zwijnenburg, Nurdan Akogul, Nancy E Hasselt, Marloes Broekmans, Franciska Haneveld, Natalia E Nowakowska, Johannes Bras,[...]. Nat Genet 2017
188
16

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Martin Peifer, Falk Hertwig, Frederik Roels, Daniel Dreidax, Moritz Gartlgruber, Roopika Menon, Andrea Krämer, Justin L Roncaioli, Frederik Sand, Johannes M Heuckmann,[...]. Nature 2015
335
16

Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
Samuel W Brady, Yanling Liu, Xiaotu Ma, Alexander M Gout, Kohei Hagiwara, Xin Zhou, Jian Wang, Michael Macias, Xiaolong Chen, John Easton,[...]. Nat Commun 2020
39
16

Cell signaling by receptor tyrosine kinases.
Mark A Lemmon, Joseph Schlessinger. Cell 2010
16

Neuroblastoma pathogenesis: deregulation of embryonic neural crest development.
Julie A Tomolonis, Saurabh Agarwal, Jason M Shohet. Cell Tissue Res 2018
54
16

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
Joachim T Siaw, Haiying Wan, Kathrin Pfeifer, Victor M Rivera, Jikui Guan, Ruth H Palmer, Bengt Hallberg. Oncotarget 2016
34
12

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
Damini Chand, Yasuo Yamazaki, Kristina Ruuth, Christina Schönherr, Tommy Martinsson, Per Kogner, Edward F Attiyeh, John Maris, Olena Morozova, Marco A Marra,[...]. Dis Model Mech 2013
43
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.